Rite Aid: Is Growth a Game Changer?

Rite Aid has seen tremendous gains with vast net income improvements, but could revenue growth spark yet another impressive stock run?

Feb 15, 2014 at 7:30AM

Rite Aid (NYSE:RAD) has seen a near-$650 million improvement to its bottom line over the last three years, without any top-line growth. Still, the company trades at a deep discount to its peers Walgreen (NASDAQ:WBA) and CVS Caremark (NYSE:CVS), but could revenue growth be key in closing that gap?

Rite Aid: Where it has been and what's occurred
To fully understand Rite Aid's recovery, and what's driven its stock price from $1 to nearly $6, you have to understand where the company had been and what it has accomplished.

If you rewind to late 2012, many were betting on bankruptcy, as it had been years since the company had earned a quarterly profit, and it was continuously losing market share to peers CVS and Walgreen.

Furthermore, from 2009 till 2012 the company's debt-to-assets ratio increased annually, from 70% to more than 85%, meaning the company appeared more set for a death spiral than a 500% recovery.

Then, the company posted its first quarterly profit in four years, of $61.9 million, which was the spark that lit this fire. Since then, the company has posted a quarterly profit in each following earnings report, and this profit alone has driven the stock to such large gains.

How it accomplished the recovery
Rite Aid's recovery can be attributed to many things: Some will say it's the company's loyalty program, and others will say the closing, remodeling, and relocating of unprofitable stores is finally starting to pay off.

However, one reason that all agree on is the patent cliff and the introduction of new generic drugs, which is something that management for Rite Aid, Walgreen, and CVS all note as being instrumental in boosting margins.

The patent cliff is a five-year period between 2011 and 2016 in which $133 billion of branded drugs are being introduced to the market as generics via patent expirations. These generics give pharmacies more pricing power, are bought in bulk, and return higher profits per script than brand drugs.

As a result, pharmacies have surged.

What's the next step?
One fact that many often forget is that Rite Aid achieved its massive gains despite no growth.

If we look back to the three quarters that sparked gains from $1, starting Dec. 20, 2012, comparable-store sales for the pharmacy were as followed:

Fiscal Quarter


Comparable-Store Sales


Dec. 20, 2012



April 11, 2013



June 20, 2013


As you can see, comparable-store sales actually worsened during this period, but it didn't stop shares of Rite Aid from surging more than 200%. That said, take a look at Rite Aid's comparable-store sales for the last three months, via monthly reports.

Month and Year

Comparable-Store Sales

November 2013


December 2013


January 2014


Clearly, Rite Aid is starting to achieve growth, something that has not been a staple in its incredible stock rally. Therefore, with the addition of growth, this could spark the next phase of gains for Rite Aid, a stock with room to run a lot higher.

Not comparable to its peers
Rite Aid's recent production of growth is not to the same level as its peers Walgreen and CVS.

In Walgreen's last quarter, it saw revenue growth of 5.9%, and like Rite Aid, it continues to see margin and net income improvements, up 68% in the same quarter. If we look to analyst expectations, Walgreen should grow another 4.8% this year.

CVS is expected to grow at the same sub-5% rate this year. Furthermore, CVS' last quarter mirrored Walgreen as well: The company grew sales by 5.8% and net income 24.7% year over year.

Therefore, CVS and Walgreen are both in better fundamental shape than Rite Aid... and are priced as such.

This fact is an important point to remember when assessing these three companies and determining upside. For example, Rite Aid trades at 19 times earnings with a profit margin of 1.2%, but if Rite Aid had CVS' margin, it would trade at about six time earnings.

This brings up the point that Rite Aid also trades at just 0.2 times sales, about one-third the valuation of its peers. Hence, Rite Aid is greatly discounted from its peers likely because it lacks the growth -- and in past years, it lacked any growth.

Room to run higher with growth
So, if Rite Aid is now growing, even if it's less than 1% annually, it stands to reason that the stock deserves a greater multiple to its peers.

Perhaps CVS and Walgreen are still worth a 100% premium to sales, based on the assumption that growth is sustainable and margins will continue to rise with new generic introductions. If so, and with Rite Aid trading at one-third to one-fourth the valuation of its peers, then shares could still increase 50%.

If the market decides that Rite Aid is worthy of the same multiple as its peers based on greater upside potential, then shares of the stock could still triple or more as the company continues to grow.

The bottom line: Rite Aid still presents a lot of upside, and with its newfound level of growth, investors should anticipate further gains should.

Demystifying Obamacare for investors
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.


Brian Nichols owns Rite Aid. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers